A new drug by the name of Tavalisse (fostamatinib disodium hexahydrate) is reportedly being investigated for use in treating adults with a low platelet count due to chronic immune thrombocytopenia (ITP) when other prior treatment options have fallen short.
Chronic immune thrombocytopenia is described as an autoimmune bleeding disorder. In patients with ITP, the blood doesn't clot as it should because of a low platelet count.
According to clinical trials, more patients who were treated with Tavalisse achieved pre-determined platelet counts, in comparison to patients who received a placebo.
FDA APPROVAL DATE: April 17th, 2018
MANUFACTURER: Rigel Pharmaceuticals, Inc.
More specific details pertaining to this drug can be viewed at:
I hope this helps others who may be investigating new and emerging treatment options.